A Randomized, Open-Label, Multicenter, Phase II Study Comparing the Effects on Proliferation and the Efficacy and Tolerability of Fulvestrant (FASLODEX®) 500 mg With Fulvestrant (FASLODEX®) 250 mg When Given as Neoadjuvant Treatment in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer (T2, 3, 4b, N0-3, M0).
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Anti-proliferative effect after 4 weeks of treatment.
AstraZeneca Faslodex Medical Science Director, MD
United States: Food and Drug Administration
|Research Site||Bentonville, Arkansas|
|Research Site||Beverly, Massachusetts|
|Research Site||Albuquerque, New Mexico|
|Research Site||Allentown, Pennsylvania|
|Research Site||Chattanooga, Tennessee|
|Research Site||Abilene, Texas|